Get the Stockscreener App
24.05
4.26%
-1.07
After Hours:
24.20
0.15
+0.62%
Janux Therapeutics Inc stock is traded at $24.05, with a volume of 511.21K.
It is down -4.26% in the last 24 hours and down -0.91% over the past month.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.
See More
Previous Close:
$25.12
Open:
$24.96
24h Volume:
511.21K
Relative Volume:
0.68
Market Cap:
$1.45B
Revenue:
$439.00K
Net Income/Loss:
$-105.64M
P/E Ratio:
-13.36
EPS:
-1.8
Net Cash Flow:
$-60.70M
1W Performance:
+0.29%
1M Performance:
-0.91%
6M Performance:
-24.39%
1Y Performance:
-48.31%
1-Day Range:
$24.02
$25.12
1-Week Range:
$23.62
$25.59
52-Week Range:
$21.97
$71.71
Janux Therapeutics Inc Stock (JANX) Company Profile
Name
Janux Therapeutics Inc
Sector
Industry
Phone
(858) 751-4493
Address
10955 VISTA SORRENTO PARKWAY, SAN DIEGO
Compare JANX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
JANX
Janux Therapeutics Inc
|
24.05 | 1.46B | 439.00K | -105.64M | -60.70M | -1.80 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Janux Therapeutics Inc Stock (JANX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-04-25 | Initiated | Guggenheim | Buy |
| Aug-19-25 | Initiated | Piper Sandler | Overweight |
| Jul-11-25 | Initiated | Raymond James | Outperform |
| Dec-03-24 | Reiterated | BTIG Research | Buy |
| Dec-03-24 | Reiterated | H.C. Wainwright | Buy |
| Nov-22-24 | Initiated | Leerink Partners | Outperform |
| Oct-24-24 | Initiated | UBS | Buy |
| Sep-06-24 | Initiated | Stifel | Buy |
| May-30-24 | Initiated | Scotiabank | Sector Perform |
| Mar-21-24 | Initiated | BTIG Research | Buy |
| Mar-20-24 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-06-23 | Initiated | Wedbush | Outperform |
| Nov-14-22 | Initiated | William Blair | Outperform |
View All
Janux Therapeutics Inc Stock (JANX) Latest News
Cubist Systematic Strategies LLC Purchases 35,511 Shares of Janux Therapeutics, Inc. $JANX - MarketBeat
Janux Therapeutics (NASDAQ:JANX) Now Covered by Truist Financial - MarketBeat
Possible Bearish Signals With Janux Therapeutics Insiders Disposing Stock - 富途牛牛
Woodline Partners LP Sells 395,092 Shares of Janux Therapeutics, Inc. $JANX - MarketBeat
Janux Therapeutics (NASDAQ:JANX) Now Covered by Guggenheim - MarketBeat
Alyeska Investment Group L.P. Purchases 63,762 Shares of Janux Therapeutics, Inc. $JANX - MarketBeat
Janux stock a new Buy at Truist on H2 catalysts (JANX:NASDAQ) - Seeking Alpha
Truist Initiates Janux Therapeutics at Buy With $100 Price Target - MarketScreener
Janux Therapeutics initiated with a Buy at Truist - TipRanks
Buy Rating for Janux Therapeutics Inc: Promising Oncology Innovations and Strategic Advancements - TipRanks
Janux Therapeutics resumed with a Buy at Stifel - TipRanks
Stifel resumes Janux Therapeutics stock coverage with Buy rating By Investing.com - Investing.com Canada
Walleye Capital LLC Makes New Investment in Janux Therapeutics, Inc. $JANX - MarketBeat
Analysts Set Janux Therapeutics, Inc. (NASDAQ:JANX) PT at $86.90 - MarketBeat
Adage Capital Partners GP L.L.C. Purchases 592,824 Shares of Janux Therapeutics, Inc. $JANX - MarketBeat
Technical Charts Suggest Momentum Shift in Janux Therapeutics Inc.2025 Biggest Moves & Verified Momentum Watchlists - beatles.ru
Janux Therapeutics Inc. Charts Flash Early Recovery Signals2025 Technical Patterns & Daily Profit Maximizing Tips - beatles.ru
MPM Bioimpact LLC Increases Stock Position in Janux Therapeutics, Inc. $JANX - MarketBeat
Can Janux Therapeutics Inc. disrupt its industryTrade Entry Summary & Smart Swing Trading Techniques - 뉴스영
Janux Therapeutics, Inc. $JANX is RA Capital Management L.P.'s 4th Largest Position - MarketBeat
Has Janux Therapeutics Inc. formed a bullish divergence2025 Investor Takeaways & Weekly Top Gainers Alerts - Newser
Trexquant Investment LP Purchases 103,114 Shares of Janux Therapeutics, Inc. $JANX - MarketBeat
Is Janux Therapeutics Inc. trading at a discountExit Point & Consistent Income Trade Ideas - خودرو بانک
Is Janux Therapeutics Inc. a candidate for recovery playJuly 2025 Action & Weekly Breakout Watchlists - Newser
Why is Janux Therapeutics Inc. stock going upEarnings Performance Report & Long-Term Capital Growth Strategies - خودرو بانک
What momentum shifts mean for Janux Therapeutics Inc.July 2025 Momentum & Technical Pattern Based Signals - Newser
Key metrics from Janux Therapeutics Inc.’s quarterly dataTrend Reversal & Risk Managed Trade Strategies - Newser
Custom watchlist performance reports with Janux Therapeutics Inc.Insider Selling & Daily Market Momentum Tracking - Newser
Why Janux Therapeutics Inc. is moving todayMarket Rally & AI Enhanced Execution Alerts - Newser
How to recover losses in Janux Therapeutics Inc. stockBreakout Watch & Low Risk High Win Rate Picks - Newser
Technical signs of recovery in Janux Therapeutics Inc.July 2025 Update & High Accuracy Swing Entry Alerts - Newser
Janux Therapeutics, Inc. $JANX Shares Sold by Paradigm Biocapital Advisors LP - MarketBeat
Real time breakdown of Janux Therapeutics Inc. stock performanceJobs Report & AI Driven Stock Movement Reports - Newser
Tools to assess Janux Therapeutics Inc.’s risk profileMarket Movers & Low Drawdown Momentum Trade Ideas - Newser
Is Janux Therapeutics Inc. showing signs of accumulationJuly 2025 Reactions & High Conviction Investment Ideas - Newser
How to integrate Janux Therapeutics Inc. into portfolio analysis tools2025 Trading Volume Trends & Real-Time Volume Surge Alerts - Newser
Is Janux Therapeutics Inc. stock a value trapJuly 2025 Reactions & Weekly Watchlist for Hot Stocks - خودرو بانک
Guggenheim initiates Janux Therapeutics stock with Buy rating on PSMA therapy - Investing.com Canada
Janux Therapeutics: Guggenheim initiates Buy rating with $72 price target. - AInvest
Bank of America Securities Reaffirms Their Buy Rating on Janux Therapeutics Inc (JANX) - The Globe and Mail
Guggenheim Initiates Janux Therapeutics at Buy With $72 Price Target - MarketScreener
Sentiment analysis tools applied to Janux Therapeutics Inc.2025 Pullback Review & Scalable Portfolio Growth Methods - Newser
Should you wait for a breakout in Janux Therapeutics Inc.July 2025 Drop Watch & Advanced Technical Signal Analysis - Newser
How to interpret RSI for Janux Therapeutics Inc. stock2025 Geopolitical Influence & AI Driven Price Predictions - Newser
Will Janux Therapeutics Inc. stock recover after recent drop2025 Technical Overview & Low Drawdown Investment Strategies - Newser
Predicting Janux Therapeutics Inc. trend using moving averagesWeekly Trade Review & High Conviction Buy Zone Alerts - Newser
Strategies to average down on Janux Therapeutics Inc.Market Sentiment Review & Entry Point Confirmation Signals - Newser
Multi asset correlation models including Janux Therapeutics Inc.Portfolio Gains Summary & High Accuracy Trade Signal Alerts - Newser
Can momentum traders help lift Janux Therapeutics Inc.July 2025 Market Mood & Precise Entry and Exit Recommendations - Newser
Janux Therapeutics Inc Stock (JANX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):